RMDResMed
$230.03-15% 1Y
$230.03
$182.8252 weeks$281.12
Latest close: back above its 200-day averageOct 9, 2026what changed →
The financials
ResMed by the numbers
ResMed (RMD) reported revenue of $1.46B in Q4 2026 (quarter ended Jun 30, 2026), up 8.6% from the same quarter a year earlier. That came with a gross margin of 59% and net income of $383M (26% of revenue). For the full year FY2026, revenue was $5.65B (+9.9% year on year) and net income $1.52B. Its largest product in Q4 2026 was Sleep And Breathing Health at $1.29B, 88% of the disclosed total, well ahead of Residential Care Software at 12%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q4 2026 | Q4 2025 | Change |
|---|---|---|---|
| Revenue | $1.46B | $1.35B | +8.6% |
| Gross profit | $861M | $820M | +5.0% |
| Operating income | $449M | $455M | −1.3% |
| Net income | $383M | $380M | +1.0% |
| Diluted EPS | $2.64 | $2.58 | +2.3% |
| Product | Revenue | Share |
|---|---|---|
| Sleep And Breathing Health | $1.29B | 88% |
| Residential Care Software | $172M | 12% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.46B (+2.3%)
Sleep And Breathing Health grew +9.4% year on yearResidential Care Software +2.9% year on year
Segment Latestquarter on quarteryear on year
- Sleep And Breathing Health$1.29B$1.29Bquarter on quarter +2.5%year on year +9.4%+2.5%+9.4%
- Residential Care Software$171.9M$171.9Mquarter on quarter +0.60%year on year +2.9%+0.60%+2.9%
Medical Instruments & Supplies
The closest names by size in the same industry